Policy Canary

Sample Report

This is what lands in your inbox.

This report is generated for a subscriber who monitors Marine Collagen Powder. When the FDA takes action affecting that ingredient, they get this — not a generic headline.

Warning Letter IssuedOct 14, 2025

Marine Collagen Powder

FDA CFSAN Warning Letters · 21 CFR 111.75(a)(1)(ii)

FDA Action

Warning Letter WL-2025-CFSAN-0847 — NovaBiotics Inc. (Oct 14, 2025). Identity testing failures for marine-sourced collagen.

Analysis

NovaBiotics failed to confirm the identity of marine collagen concentrate through appropriate laboratory testing prior to use. The FDA cited missing ingredient-specific identity tests — COA-only documentation was deemed insufficient.

Required Actions

  1. 1Audit your identity testing protocols for marine collagen against 21 CFR 111.75(a)(1)(ii)
  2. 2Verify COA documentation includes marine collagen-specific identity tests, not just generic protein analysis
  3. 3Confirm with your contract manufacturer that identity tests are performed per batch, not per lot
Review complete by Q2 2026

What free subscribers see

FDA Updates Identity Testing Requirements for Marine-Sourced Supplements — Oct 14, 2025

No product match. No action items. No analysis.

Add your products.
Get this in your inbox.

Free weekly digest to start. When you add your products, we match every FDA action against your specific ingredients.

We'll personalize based on the products you add after signup.